NanoDel Technologies GmbH
NanoDel is a biopharmaceutical company that uses its proprietary brain delivery technology to develop drugs for the treatment of brain tumors and other diseases of the central nervous system (CNS).
95% of all therapeutics that in principle are suitable for the treatment of CNS diseases do not pass the BBB in therapeutically relevant doses. In order to overcome this limitation NanoDel developed a patent protected nanoparticle based technology (particles are made out of poly-butylcyano-acrylate) which allows or improve the transport of pharmaceutical active compounds loaded into nanoparticles (NP) across the BBB. In addition, pharmaco-kinetic and-dynamic drug parameters can be improved.
NanoDel is using its nanoparticle based technology to deliver compounds that are suitable for the treatment of brain tumors and other acute and chronic CNS related disorders, such as brain infections, neuroprotection, migraine, epilepsy, Alzheimer’s and others.
The following NP packed compounds are under pre-clinical development or in feasibility studies:
- Doxorubicin-nanoparticles against glioblastoma are in pre-clinical development.
- Thalidomid-nanoparticles against glioblastoma are in preparation for pre-clinical development.
- Progesteron for neuroprotection is under evaluation concerning its "loadability" into NPs (feasibility study).
- Additional feasibility studies with CNS development compounds from other pharma companies are ongoing as a fee for service approach.
NanoDel’s technology is protected by 4 patents already issued, and 2 patent applications. Additional drug related use patents are in preparation.
NanoDel will develop nanoparticle loaded compounds up to clinical proof of concept. From phase IIb onwards a co-development pharma partner is required.